Transfusion medicine problems and solutions for the pediatric hematologist/oncologist

Pediatric Blood and Cancer

Volumn 58, Issue 7, 2012, Pages 1106-1111

  Luban, Naomi L C ^a   McBride, Eileen ^b   Ford, Jason C ^c   Gupta, Sumit ^d  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Alloimmunization; Blood transfusion; Platelet refractoriness; Review; Sickle cell disease; Stem cell transplantation; Thalassemia

Indexed keywords

BLOOD GROUP ANTIGEN; HLA A ANTIGEN; HLA B ANTIGEN; RHESUS ANTIGEN; ALLOANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNIZATION; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; AUTOIMMUNITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CLOTTING PARAMETERS; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; BLOOD RADIATION; BLOOD TRANSFUSION REACTION; BLOOD VISCOSITY; CHILD CARE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; DONOR; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMOLYSIS; HEMOLYTIC ANEMIA; HEREDITARY HEMOLYTIC ANEMIA; HLA MATCHING; HUMAN; INFECTION RISK; IRON OVERLOAD; MORBIDITY; MORTALITY; PLATELET REFRACTORINESS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SICKLE CELL ANEMIA; THALASSEMIA; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; CHILD; DOSE RESPONSE; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; ONCOLOGY; PEDIATRICS;

ABO BLOOD-GROUP SYSTEM; CHILD; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOANTIBODIES; MEDICAL ONCOLOGY; PEDIATRICS; PLATELET TRANSFUSION;

EID: 84861703868     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24077     Document Type: Review

References (62)

1. O'Brien KL, Champeaux AL, Sundell ZE, et al. Transfusion medicine knowledge in postgraduate year 1 residents. Transfusion 2010;50:1649-1653.
2. Rock T, Berger R, Pinkerton P, et al. A pilot study to assess physician knowledge in transfusion medicine. Transfus Med 2002;12:125-128.
3. Wilson K, MacDougall L, Fergusson D, et al. The effectiveness of interventions to reduce physician's levels of inappropriate transfusion: What can be learned from a systematic review of the literature. Transfusion 2002;142:1224-1229.
4. Hillyer CD, Strauss RG, Luban NLC. Handbook of pediatric transfusion medicine. San Diego, CA: Elsevier Academic Press; 2004.
5. Roback JD. AABB technical manual. Bethesda, MD: American Association of Blood Banks; 2011.
6. Wong EC, Perez-Albuerne E, Moscow JA, et al. Transfusion management strategies: A survey of practicing pediatric hematology/oncology specialists. Pediatr Blood Cancer 2005;44:119-127.
7. Vassallo RR, Murphy S. A critical comparison of platelet preparation methods. Curr Opin Hematol 2006;13:323-330.
8. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematol Am Soc Hematol Educ Program 2007; 172-178.
9. Whitaker BI, Green J, King MR, et al. The 2007 national blood collection, utilization survey. Washington, DC: The Department of Health and Human Services; 2007. 1-65 p.
10. Strauss RG. Platelet transfusions in neonates: Questions and answers. Expert Rev Hematol 2010;3:7-9.
11. Daly PA, Schiffer CA, Aisner J, et al. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for hla-matched preparations. JAMA 1980;243:435-438.
12. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142:348-360.
13. The Trial to Reduce Alloimmunization to Platelets Study Group (TRAP). Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869.
14. Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet refractoriness: Correlation with bleeding and survival. Transfusion 2008;48:1959-1965.
15. Schiffer CA. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev 2001;15: 175-180.
16. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1519-1538.
17. Pavenski K, Warkentin TE, Shen H, et al. Post-transfusion platelet count increments after ABOcompatible versus ABO-incompatible platelet transfusions in noncancer patients: An observational study. Transfusion 2010;50:1552-1560.
18. Shehata N, Tinmouth A, Naglie G, et al. ABO-identical versus nonidentical platelet transfusion: A systematic review. Transfusion 2009;49:2442-2453.
19. Carr R, Hutton JL, Jenkins JA, et al. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990;75:408-413.
20. Duguid JK, Minards J, Bolton-Maggs PH. Lesson of the week: Incompatible plasma transfusions and haemolysis in children. Br Med J 1999;318:176-177.
21. Blumberg N, Heal JM, Hicks GL, Jr, et al. Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 2001;41:790-793.
22. Rebulla P. Platelet transfusion trigger in difficult patients. Transfus Clin Biol 2001;8:249-254.
23. British Committee for Standards in Haematology Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10-23.
24. Transfusion of apheresis platelets and ABO groups. Vox Sang 2005;88:207-221.
25. Lozano M, Heddle N, Williamson LM, et al. Practices associated with ABO-incompatible platelet transfusions: A best collaborative international survey. Transfusion 2010;50:1743-1748.
26. Slichter SJ, Davis K, Enright H, et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-4114.
27. Sacher RA, Kickler TS, Schiffer CA, et al. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 2003;127:409-414.
28. McVey MC, Serti-Gazdewich CM. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA. Transfus Med 2010;20:346-353.
29. Hannon J, Hume H. CMV seronegative, irradiated and washed blood components. In: Clarke G, Blajchman M, editors. Clinical guide to transfusion. Toronto: Canadian Blood Services; 2006. p 146-153.
30. Pisciotto PT. Cytomegalovirus safety issues in neonatal transfusion. In: Herman JH, Manno CS, editors. Pediatric transfusion therapy. Bethesda: AABB Press; 2002. p 171-192.
31. Roback JD. CMV and blood transfusions. Rev Med Virol 2002;12:211-219.
32. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocomprimised patients and means for reduction. Br J Haematol 2004;125:107-116.
33. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus after receipt of leukoreduced blood products. Blood 2003;101:4195-4200.
34. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Trans Med Rev 2005;19:181-199.
35. Blajchman MA, Goldman M, Freedman JJ, et al. Proceedings of a consensus conference: Prevention of post-transfusion cmv in the era of universal leukoreduction. Trans Med Rev 2001;15:1-20.
36. Roback JD. Preparation of blood componenets to reduce cytomegalovirus and other infectious risks. In: Hillyer CD, Strauss RG, Luban NLC, editors. Handbook of pediatric transfusion medicine. New York: Elsevier; 2004. p 93-99.
37. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2009;108: z759-769.
38. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008;112:2617-2626.
39. Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: Risk due to homozygous HLA haplotypes. Transfusion 1995;35:284-291.
40. Serious Hazards of Transfusion-United Kingdomt (SHOT-UK). Serious hazards of transfusion for children. Retrieved August 21, 2011 from http://www.shotuk.org/wp-content/uploads/2010/03/SHOTfor-Children.pdf.
41. Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABOincompatible bone marrow transplantation. Blood 1990;75:2905.
42. Kaufman RM, Sloan SR. Transfusion to bone marrow or solid organ transplant recipients. In: Hillyer CD, Silberstein LE, Ness PM, et al., editors. Blood banking and transfusion medicine. Philadelphia: Elsevier; 2007. p 539-550.
43. Yazer MH. Immune hemolysis following abo-mismatched stem cell or solid organ transplantation. Curr Opin Hematol 2007;14:664-670.
44. Maciej Zaucha J, Mielcarek M, Takatu A, et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible stem cell transplantation. Br J Haematol 2002;119:740-750.
45. Sokol RJ, Stamps R, Booker DJ, et al. Post-transplant immune-mediated hemolysis. Transfusion 2002;42:198-204.
46. Hows J, Beddow K, Gordon-Smith E, et al. Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. Blood 1986;67:177-181.
47. Hoffman PC. Immune hemolytic anemia-Selected topics. Hematology 2006; 13-18.
48. Worel N, Greinix HT, Keil F, et al. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood cell transplantation occurs more frequently after nonmyelobablative than myeloablative conditioning. Transfusion 2002;42:1293-1301.
49. Leo A, Mytilineos J, Voso MT, et al. Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jk(a) after allogeneic PBPC transplantation. Transfusion 2000;40:632-636.
50. Gorlin J, Grupp S. Transfusion support in pediatric oncology and hematopoietic transplantation. In: Herman JH, Manno CS, editors. Pediatric transfusion therapy. Bethesda: AABB Press; 2002. p 421-440.
51. Adams RJ, McVie VC, Hsu L, et al. Prevention of a first stroke by transfusions in chidlren with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998;339:5-11.
52. Kwiatkowski JL, Yim E, Miller S, et al. Effect of transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer 2011;56:777-782.
53. Venkateswaran L, Teruya J, Bustillos C, et al. Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease. Pediatr Blood Cancer 2011;57:294-296.
54. Singer ST, Quirolo K, Nishi K, et al. Erythrocytapheresis for chronically transfused children with sickle cell disease: An effective method for maintaining a low hemoglobin s level and reducing iron overload. J Clin Apher 1999;14:122-125.
55. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617-1621.
56. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990;76:1431-1437.
57. Thompson AA, Cunningham MJ, Singer ST, et al. Red cell alloimmunization in a diverse popluation of transfused patients with thalassaemia. Br J Haematol 2011;153:121-128.
58. Osby M, Shulman IA. Phenotype matching of donor red blood cell units for non-alloimmunized sickle cell disease patients: A survey of 1182 North American laboratories. Arch Pathol Lab Med 2005;129:190-193.
59. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: A multicenter transfusion trial. Transfusion 2001;41:1086-1092.
60. Aygun B, Padmanabhan S, Paley C, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43.
61. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell diseae: A review of a 14-year experience from a single center. Transfusion 2011;51:1732-1739.
62. Castellino SM, Combs MR, Zimmerman SA, et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: Frequency, characteristics and significance. Br J Haematol 1999;104:189-194.